ARDS - Aridis Pharmaceuticals, Inc.
| Previous Close | 6.02 |
| Open | 6.10 |
| Bid | 6.02 x 800 |
| Ask | 6.20 x 1200 |
| Day's Range | 6.00 - 6.00 |
| 52 Week Range | 5.37 - 13.00 |
| Volume | 130 |
| Avg. Volume | 10,356 |
| Market Cap | 53.473M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.19 |
| Earnings Date | Aug 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.75 |
- Simply Wall St.
Introducing Aridis Pharmaceuticals (NASDAQ:ARDS), The Stock That Slid 52% In The Last Year
The nature of investing is that you win some, and you lose some. Unfortunately, shareholders of Aridis...
- PR Newswire
Aridis Pharmaceuticals Appoints Infectious Disease Expert Paul Mendelman, MD as Interim Chief Medical Officer
SAN JOSE, Calif. , Oct. 11, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to ...
- PR Newswire
Aridis Pharmaceuticals Executes License Agreement with The Serum Institute of India, Ltd. for Exclusive Rights to Products and Utilization of MabIgX® Platform Technology
SAN JOSE, Calif., Sept. 30, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today that it has consummated a licensing agreement with Serum AMR, an affiliate of Serum International BV (SIBV) and the Serum Institute of India, Ltd. The agreement grants Serum AMR a license to multiple programs from Aridis for certain limited territories and access the Company's MabIgX® platform technology for asset identification and selection. As part of the agreement, Aridis will receive the remaining upfront cash payment of $10 million, which is in addition to the $5 million that was initially received when the companies signed an option agreement on July 30, 2019.
- PR Newswire
Aridis Pharmaceuticals to Present AR-105 and AR-501 (Gallium Citrate) Data at IDWeek™ 2019
SAN JOSE, Calif. , Sept. 27, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to ...
- PR Newswire
Aridis Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
SAN JOSE, Calif. , Sept. 27, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to ...
- PR Newswire
Aridis Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference on September 10, 2019
SAN JOSE, Calif. , Sept. 8, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to ...
- MarketWatch
Aridis Pharmaceuticals stock plunges after drug trial fails to meet primary endpoint
Shares of Aridis Pharmaceuticals Inc. plunged 27% to pace all premarket decliners Tuesday, after the biopharmaceutical company said a phase 2 trial of its treatment of ventilator-associated pneumonia (AR-105) failed to meet the primary endpoint, which was superiority as compared with placebo. The company said there was also a statistically significant imbalance in all-cause mortality, as well as serious adverse event rates. "At this point, the company will no longer allocate further development resources to AR-105," the company said in a statement. The stock had run up 29.7% over the past three months through Friday, while the iShares Nasdaq Biotechnology ETF has gained 1.9% and the S&P 500 has tacked on 6.6%.
- PR Newswire
Aridis Pharmaceuticals Reports Phase 2 Clinical Trial Results of AR-105 for the Treatment of Ventilator-Associated Pneumonia Caused by Pseudomonas Aeruginosa
SAN JOSE, Calif. , Sept. 3, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) , a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to ...
- PR Newswire
Aridis Pharmaceuticals Announces Second Quarter 2019 Results
SAN JOSE, Calif. , Aug. 12, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully ...
- Simply Wall St.
Do Insiders Own Lots Of Shares In Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS)?
A look at the shareholders of Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) can tell us which group is most powerful...
- PR Newswire
Aridis Pharmaceuticals Enters Into Equity Purchase and Option Agreements with The Serum Institute of India, Ltd for Exclusive License to Products and MabIgX® Platform Technology
SAN JOSE, Calif., July 30, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal antibodies (mAbs) to treat life-threatening bacterial infections, announced today that it has entered into an option agreement with the Serum International BV ("SIBV"), an affiliate of Serum Institute of India, Ltd., the world's largest vaccine manufacturer by dose units. The agreement grants SIBV the option to license multiple programs from Aridis and access the Company's MabIgX® platform technology for asset identification and selection. As part of the option agreement, SIBV made an equity investment of $10 million whereby Aridis will issue 801,820 shares of its restricted common stock to SIBV at a price of approximately $12.47 per share which represents approximately 31% premium to yesterday's closing share price.
- PR Newswire
Aridis Pharmaceuticals Receives Orphan Drug Designation From the European Medicines Agency for AR-501
SAN JOSE, Calif. , July 19, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) announced today that the European Medicines Agency (EMA) has granted Orphan Drug Designation to AR-501, the ...
- PR Newswire
Aridis Pharmaceuticals Receives Orphan Drug Designation for AR-501
SAN JOSE, Calif. , June 27, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies for life-threatening ...
- PR Newswire
Aridis Pharmaceuticals Appoints Dr. Susan Windham-Bannister to Board of Directors
SAN JOSE, Calif. , June 10, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully ...
- PR Newswire
Aridis Pharmaceuticals Announces First Quarter 2019 Results
SAN JOSE, Calif. , May 14, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully ...
- Zacks
Will Aridis Pharmaceuticals Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Aridis Pharmaceuticals.
- Zacks
Aridis Pharmaceuticals (ARDS) Upgraded to Buy: Here's Why
Aridis Pharmaceuticals (ARDS) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- PR Newswire
Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update
SAN JOSE, Calif. , March 28, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully ...
- Simply Wall St.
Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) Has Attractive Fundamentals
Attractive stocks have exceptional fundamentals. In the case of Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), there's is a company with strong financial health as well as a excellent growth outlook. Below, I've Read More...
- PR Newswire
AR-501 (Cystic Fibrosis) Enrolls First Subject in Phase 1/2a Clinical Trial for Treatment of Chronic Lung Infections in Cystic Fibrosis Patients
- Two-Part Randomized, Double-Blinded Placebo Controlled Clinical Study in Healthy Subjects Followed by Cystic Fibrosis Patients Enrolls First Adult Human Volunteer - Study Being Performed in Collaboration ...
- PR Newswire
Aridis Expands Research Agreement with the Cystic Fibrosis Foundation and is Awarded FDA Expedited Program Designations
- CF Foundation expands research agreement for AR-501 (for cystic fibrosis) to include additional award amount of up to $4.6 million - FDA grants Fast-Track and QIDP Designations for AR-501, enabling future ...
